ArticleCell death & disease2026
PMEPA1 modulates YAP1 nuclear translocation to disrupt EMT subtypes and promote metastasis in Biliary tract cancer.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Biliary tract cancer (BTC) is an aggressive tumor with poor prognosis and limited treatment options. Epithelial-mesenchymal transition (EMT) significantly contributes to BTC metastasis, yet the critical regulators and underlying molecular mechanisms of EMT remain poorly unclear. In our study, we conducted an integrative analysis of single-cell RNA sequencing (scRNA-seq) data from 47 BTC samples, identifying two EMT-enriched epithelial subpopulations and a BTC specific EMT gene set. Using the EMT gene set, we classified BTC patients and noticed that those with elevated EMT scores had worse prognoses. Additionally, multi-omics analyses identified PMEPA1 as a pivotal EMT regulator, with its high expression levels correlating with adverse prognosis and distant metastasis. Functional assays revealed that PMEPA1 knockdown inhibits, while its overexpression promotes EMT progression by modulating Hippo-YAP signaling, specifically YAP1 nuclear localization. Moreover, we forecast and validated topoisomerase inhibitor SN-38 as a potential EMT-targeting agent. SN-38 effectively inhibited BTC cell migration and metastasis in vivo, likely by attenuating the transcriptional activity of PMEPA1 and its upstream regulator FOS. Overall, this research elucidates EMT-related molecular features in BTC, reveals PMEPA1 as a critical EMT driver via the Hippo-YAP1 pathway, and proposes SN-38 as a promising therapeutic candidate, offering new insights into BTC metastasis and precision therapy. Our study identifies PMEPA1 as a central regulator of EMT and metastasis in BTC. The PMEPA1-a isoform bypasses the tumor-suppressive Hippo pathway by inhibiting LATS1/2 kinase activity. This liberates YAP1 to translocate into the nucleus and initiate a pro-EMT gene expression program. Finally, we demonstrate that the drug candidate SN-38 suppresses metastasis by interfering with this PMEPA1/YAP1 signaling module.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.